scholarly journals Environment and the Inflammatory Bowel Diseases

2013 ◽  
Vol 27 (3) ◽  
pp. e18-e24 ◽  
Author(s):  
Alexandra Frolkis ◽  
Levinus A Dieleman ◽  
Herman W Barkema ◽  
Remo Panaccione ◽  
Subrata Ghosh ◽  
...  

Inflammatory bowel diseases (IBD), which consists of Crohn disease and ulcerative colitis, are chronic inflammatory conditions of the gas-trointestinal tract. In genetically susceptible individuals, the interaction between environmental factors and normal intestinal commensal flora is believed to lead to an inappropriate immune response that results in chronic inflammation. The incidence of IBD have increased in the past century in developed and developing countries. The purpose of the present review is to summarize the current knowledge of the association between environmental risk factors and IBD. A number of environmental risk factors were investigated including smoking, hygiene, microorganisms, oral contraceptives, antibiotics, diet, breast-feeding, geographical factors, pollution and stress. Inconsistent findings among the studies highlight the complex pathogenesis of IBD. Additional studies are necessary to identify and elucidate the role of environmental factors in IBD etiology.

2010 ◽  
Vol 45 (12) ◽  
pp. 1464-1471 ◽  
Author(s):  
Pilar López-Serrano ◽  
José L. Pérez-Calle ◽  
Maria Teresa Pérez-Fernández ◽  
Juan Manuel Fernández-Font ◽  
Daniel Boixeda de Miguel ◽  
...  

2019 ◽  
Vol 157 (3) ◽  
pp. 647-659.e4 ◽  
Author(s):  
Daniele Piovani ◽  
Silvio Danese ◽  
Laurent Peyrin-Biroulet ◽  
Georgios K. Nikolopoulos ◽  
Theodore Lytras ◽  
...  

2021 ◽  
Vol 10 (4) ◽  
pp. 853
Author(s):  
Giuseppe Privitera ◽  
Daniela Pugliese ◽  
Gian Ludovico Rapaccini ◽  
Antonio Gasbarrini ◽  
Alessandro Armuzzi ◽  
...  

Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gastrointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogeneity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction of the first biological therapies, the pipeline of therapies for IBD has been constantly expanding, and a significant number of new molecules is expected in the next few years. Evidence from clinical trials and real-life experiences has taught us that up to 40% of patients do not respond to a specific drug. Unfortunately, to date, clinicians lack a valid tool that can predict each patient’s response to therapies and that could help them in choosing what drug to administer. Several candidate biomarkers have been investigated so far, with conflicting results: clinical, genetic, immunological, pharmacokinetic and microbial markers have been tested, but no ideal marker has been identified so far. Based on recent evidence, multiparametric models seemingly hold the greatest potential for predicting response to therapy. In this narrative review, we aim to summarize the current knowledge on predictors and early markers of response to biological therapies in IBD.


Sign in / Sign up

Export Citation Format

Share Document